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Autoimmune processes can be found in physiological circumstances. However, they are quenched with properly functioning
regulatory mechanisms and do not evolve into full-blown autoimmune diseases. Once developed, autoimmune diseases are
characterized by signature clinical features, accompanied by sustained cellular and/or humoral immunological abnormalities.
Genetic, environmental, and hormonal defects, as well as a quantitative and qualitative impairment of immunoregulatory functions,
have been shown in parallel to the relative dominance of proinflammatory Th17 cells in many of these diseases. In this review
we focus on the derailed balance between regulatory and Th17 cells in the pathogenesis of autoimmune diseases. Additionally,
we depict a cytokine imbalance, which gives rise to a biased T-cell homeostasis. The assessment of Th17/Treg-cell ratio and the
simultaneous quantitation of cytokines, may give a useful diagnostic tool in autoimmune diseases. We also depict the multifaceted
role of dendritic cells, serving as antigen presenting cells, contributing to the development of the pathognomonic cytokine signature
and promote cellular and humoral autoimmune responses. Finally we describe the function and role of extracellular vesicles
in particular autoimmune diseases. Targeting these key players of disease progression in patients with autoimmune diseases by
immunomodulating therapy may be beneficial in future therapeutic strategies.
1. Introduction
Autoimmune diseases are typically multietiological enti-
ties, where genetic and environmental abnormalities along
with derailed immunoregulatory processes contribute to the
development of disease. In the healthy immune system,
various tolerance mechanisms, such as activation-induced
cell death, anergy, or clonal ignorance, play a protective role
to prevent the activation of self-reactive lymphocytes [1].
In autoimmune conditions, self-reactive lymphocytes may
not be subjected to the aforementioned tolerance mecha-
nisms raising the possibility of the survival and activation
of autoreactive T and B cells upon autoantigen encounter
[2–4]. However, there is a fine line between autoimmune
processes, which also appear in healthy individuals and
manifested autoimmune diseases. In autoimmune diseases,
one or several tolerance mechanisms permanently fail due
to the constellation of various environmental factors, specific
HLA- and non-HLA genes and/or derailed immunoregu-
latory processes, leading to the persistence of self-reactive
T- and B-cell clones and ultimately organ damage [4, 5].
Immunoregulatory abnormalities and/or the imbalance of
immunoregulatory and inflammatory processes could lead to
the progression towards autoimmune diseases. Besides faulty
tolerance mechanisms, several other factors, such as imbal-
ance of the pro- and anti-inflammatory cytokines, extracel-
lular vesicles, abnormal autoantigen scavenging machinery,
and antigen presentation, can contribute to the development
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and perpetuation of autoimmune processes and eventually to
the progress towards autoimmune diseases. Herein we aim
to address some selected pathogenetic points in the develop-
ment of autoimmune diseases.
2. Animal Models of Autoimmunity
Acquired immunity has evolved with an intricate control sys-
tem to balance pro- and anti-inflammatory responses. Auto-
immunity or immunity toward “self ” is a pathological pro-
cess that involves autoreactive B cells and corresponding
autoantigen-specific T cells, imbalances in cytokine levels,
and a shifted leukocyte polarization profile. In most of these
diseases, a proinflammatory environment dominates, with a
Th1 (type 1 insulin-dependent diabetes mellitus, Hashimoto’s
thyroiditis), Th17 (multiple sclerosis), or combined Th1/Th17
(Sjo¨gren’s syndrome) signature. Animal models of autoim-
munity have been important research tools for many years
now, aiding to pinpoint various components of the patho-
genesis of human autoimmune diseases. Today, more than
80 types of autoimmune pathologies are recognized, most
with distinct clinical profiles. Animal models have been
developed for all themajor disease entities, for example, type 1
diabetes mellitus (T1D), rheumatoid arthritis (RA), multiple
sclerosis (MS), Sjo¨gren’s syndrome (SS), and systemic lupus
erythematosus (SLE). Based on the etiological background
and induction of symptoms these animal models can be
divided into three broad categories: spontaneous, induced,
and genetically engineered. The strengths and weaknesses of
each are briefly discussed below.
2.1. SpontaneousModels of Autoimmunity. Susceptible rodent
strains spontaneously develop autoimmunity. Well-known
examples include the NOD mouse that develops T1D and
inbred mice (MRL/lpr, NZB/KN, and Biozzi) that develop
arthritis. NOD mice have been extremely useful in delineat-
ing the basic principles of T1D [1]. As in humans, so in both
NOD mice and susceptible BB rats, T1D is dependent on a
collection of genetic traits rather than a single gene [6]. The
dependence of T1D on autoreactive T cells and the resolution
of disease through T-cell modulation have been important
proofs of principles observed in NOD mice. In NOD mice,
the sequential development of human T1D is well reca-
pitulated, starting with peri-insulitis (leukocytic infiltration
into periductal areas, 3–6 weeks) followed by intrainsulitis
(islets are invaded by inflammatory cells recognizing 𝛽-cell
autoantigens) and diabetes (T cell-mediated destruction of
islets, 10–30 weeks).
A recent spontaneous model for MS is the relapsing-
remitting mouse (RR mouse). RR mice harbor increased
frequencies of myelin-specific CD4 T cells and are on a
SJL/J background [7]. This model is unique, as it resembles
humanMS in the dependence on autoreactive B cells and the
production of autoantibodies and develops without artificial
induction [8]. A proof of principle for the contribution of
gut microbiota to MS development by T-cell activation has
been shownusing thismodel system [9]. Along these lines the
contribution of viruses or bacteria as triggers for autoimmune
diseases is an important field of study that would benefit from
animal models.
2.2. InducedModels. Systemic autoimmunitymay be induced
in rodents after injection of the lipid pristane (tetram-
ethylpentadecane; leading to SLE and RA), mercury, or
foreign grafts (leading to graft versus host disease, GVHD).
Animal models of organ-specific autoimmunity are estab-
lished by administering a tissue-derived self-antigen (or
a peptide thereof) together with a strong adjuvant. Well-
known models are collagen induced arthritis (CIA) for RA
and experimental allergic encephalomyelitis (EAE) for MS.
For CIA, intradermal injection of collagen type II together
with adjuvant activates autoreactive B and T cells. In sus-
ceptible rat strains, such as DA, Freund’s adjuvant alone
induces arthritis (AA). CIA successfully recapitulates human
RA histopathology, with synovial joint inflammation and
bone erosion. Regarding the disease course, pristane-induced
arthritis more closely resembles chronic, relapsing-remitting
human RA, whereas AA usually shows rapid remission.
To induce EAE, CNS antigens in adjuvant are used for
immunization or myelin-specific Th1 cells are transferred to
susceptible strains, such as Lewis rats. In contrast to human
MS, which is relapsing-remitting or develops progressively,
EAE induced after T-cell transfer to rats has a monophasic
disease course [10]. Although proinflammatory lymphocytic
infiltration is achieved, themassive demyelination seen inMS
is not consistently recapitulated [11]. A major drawback of
inducible models is that they are not suitable to elucidate the
etiology of the disease and typically fail to recapitulate the full
scale of pathological traits associated with human autoimmu-
nity. The disease course in humans with a given diagnosis
is often diversified, whereas that in the mouse is highly pre-
dictable. Within inbred rodent strains, genetic homogeneity,
a homogenous environmental milieu, and the evolutionary
distance from humans certainly contribute to this effect.
2.3. Genetically Engineered Models. Throughout the 1980s,
with the aid of more advanced techniques in cell and molec-
ular biology such as gene cloning andmouse embryonic stem
cell manipulation technology, more representative rodent
models have been generated.These technologies enabled sci-
entists to generate novel mouse strains with defined genetic
changes suspected to contribute to autoimmunity (e.g.,
expression of defined MHC alleles or selected cytokines).
Furthermore, these technologies allowed researchers to clone
and sequence T-cell lines specific for autoantigens. The T-
cell lines were instrumental for transfer experiments and for
engineering T-cell receptor knock-in mice [12]. Transgenic
mice that express defined human or mouse MHC class II
alleles have been successful in recapitulating a whole range
of autoimmune pathologies, most notably multiple sclerosis,
chronic inflammatory bowel disease, and myasthenia gravis
[13]. Mice engineered to express full length human TNF-
𝛼 spontaneously develop chronic inflammatory polyarthritis
[14]. Proof of principle for TNF-𝛼 blockade in treating RA
has been obtained in this model, an early success story for
translational research. Transgenic expression of the human
Mediators of Inflammation 3
T-lymphotropic virus-1 genome leads to the development of
arthritis in mice and this model suggested the role of this
virus in the development of human RA [15, 16]. A major
advantage of such genetically engineered models is that the
induced changes (genes) can be precisely defined and experi-
mentally controlled through comparisons with the parental
background strain. Furthermore, they allow for spatial and
temporal control of gene expression, through tissue specific
or inducible promoters. In addition, expression of a fluo-
rescent or luminescent reporter facilitates in vivo imaging
approaches.
2.4. General Considerations. Ideally, an animal model should
reflect the whole range of features associated with human
pathology, not only isolated traits thereof. If it is a genet-
ically targeted model, it should rely on homologues of
genes/pathways known to be responsible for autoimmunity
in humans. Finally, it is desirable that the disease develops
spontaneously, so that the etiology of the given syndrome
may be investigated. Although none of the animal models
have all these features, they have, in concert, been invaluable
tools that have shed light on basic disease mechanisms.
This has been important, since in many human autoimmune
diseases, progression is typically correlated only to serum
markers with the pathological tissue being inaccessible (such
as T1D or MS) or limited (RA or SS). With the application
of more refined imaging techniques, such as PET/CT and
intravitalmicroscopy, animalmodels will continue to provide
useful mechanistic insights into metabolic parameters, dis-
ease course, and pathways of leukocyte migration. We argue
that for any given autoimmune disease, scientific evidence
collected from several animal models, inducible, genetically
modified, and spontaneous, correlated with clinical param-
eters and characterization of biopsy/autopsy tissue will be
needed to extract more biological information with relevance
to human pathology.
3. The Role of Regulatory T Cells in
Autoimmune Diseases
The fine balance between pro- and anti-inflammatory pro-
cesses within the immune system is crucial to maintain the
antigenic integrity of the individual, while at the same time
must effectively eliminate pathogens. A spectrum of char-
acteristic immunocompetent cell populations exists, which
have the capability to suppress immune and autoimmune
processes. These suppressor activities can be achieved by
either cell-cell contact or via anti-inflammatory soluble
mediators, for example, anti-inflammatory cytokines. A key
member of the family of immunoregulatory cells is denoted
as regulatory T cells (Tregs). Tregs derive either from the
thymus [CD4+CD25brightFoxP3+ natural Tregs (nTregs)] or
the peripheral blood [IL-10, or TGF-𝛽 producing Type-1 reg-
ulatory T cells (Tr1)] [17]. Under pathological circumstances,
when quantitative and/or qualitative changes in regulatory
T cells and proinflammatory immune responses are evoked,
on a susceptible genetic background, autoimmune processes
can occur, and eventually various autoimmune diseases can
develop. In line with this hypothesis, previous studies on
autoimmune disease depicted that the selective decrease in
the number of Tregs or, alternatively, a diminished suppressor
function of Tregs is characteristic to these diseases (e.g.,
SLE, Sjo¨gren’s syndrome, RA, and MCTD) [18–22]. These
data indicate that in patients with established autoimmune
diseases a sustained impairment of the regulatory T-cell pool
exists.
In order to assess whether regulatory T-cell abnormalities
could contribute to the development of autoimmune diseases,
it is valuable to assess Tregs in medical conditions, predating
the onset of full-blown diseases. In the forerunner med-
ical condition for systemic autoimmune diseases, denoted
as undifferentiated connective tissue disease (MCTD), the
assessment of Treg cells showed that the percentage and
absolute number of natural Tregs (CD4+CD25brightFoxP3+)
were diminished in UCTD patients compared with healthy
subjects, while the number of inducible Tregs (CD4+IL-10+)
was increased [23].This progressive divergent shift in natural
and induced Tregs clearly predicted the transition from the
UCTD, introductory phase to a well-established systemic
autoimmune disease [23]. In active systemic autoimmune
diseases, the frequency of natural Tregs was found to be
decreased compared to healthy individuals or compared to
patients with inactive disease [18, 20, 24]. The other major
regulatory T-cell subset denoted as IL-10 producing Type-1
regulatory T cells (CD4+IL-10+, Tr1) has been investigated
and found to have an important role in the development
of various autoimmune diseases [25]. IL-10, also known as
human cytokine synthesis inhibitory factor (CSIF), is a mul-
tifunctional cytokine that can suppress the IFN-𝛾 production
of Th1 cells as well as having other important regulatory
functions in differentiation of various T-cell subsets, B cells,
or NK cells [26, 27]. Previously we have shown a significant
increase in the number of IL-10 producing Tr1 cells in UCTD
and we found further increase in patients who progressed
into definitive systemic autoimmune diseases.We believe that
this phenomenon represents a compensatory mechanism in
order to downmodulate the effects of the observed IFN-𝛾
overproduction [23].
4. The Role of Th17 Cells and the Th17/Treg
Ratio in Autoimmune Diseases
Upon particular, proinflammatory conditions, T cells have
the ability to differentiate into IL-17-producing T helper cells,
denoted as Th17 cells, and this differentiation is independent
of Th1 or Th2 cell development [28, 29]. Th17 polarization
in humans requires IL-1𝛽, IL-6, IL-21, and IL-23, which
induce STAT3.WhileTh17 cells are important in host defense
mechanisms against pathogens, the persistent secretion of
IL-17 promotes chronic inflammation and is involved in
the pathogenesis of inflammatory and autoimmune diseases.
Th17 cells recruit neutrophils and macrophages to the site of
inflammation; therefore, they are crucial in the initiation of
inflammation [29]. As we described, increased levels of Th17
cells and secreted IL-17 have been associated with numerous
inflammatory conditions and autoimmune diseases. High
levels of IL-17 have been described in the sera, synovial
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fluids, and synovial biopsies of most RA patients, while
osteoarthrosis showed no increased levels of this cytokine
[30, 31]. In other systemic autoimmune diseases, IL-17 and
Th17 cells may play a role in the pathogenesis, indicated by
studies on SLE, or patients with lupus nephritis [32, 33]. In
Sjo¨gren’s syndrome, an increase in IL-17 has been found in
both the serum and the affected salivary glands, indicating
that the cytokine may play a part in both development of the
glandular and systemic manifestations of the disease [34, 35].
As mentioned earlier, the imbalance of pro- and anti-
inflammatory mechanisms, indicated by, for example, Th17
and Treg numbers or function, may initiate and perpet-
uate autoimmune diseases. Tregs develop in the thymus
and participate in the maintenance of peripheral tolerance;
however, circulating and local skewed cytokine milieu alters
the suppressive function of these cells [36]. Focally, in affected
organs of patients with autoimmune diseases increased IL-
6 and TGF-𝛽 expression has been described, which favors
the development of Th17 cells. In addition, increased con-
centrations of TNF-𝛼, which is pathognomonic to many
autoimmune diseases, downmodulate the function of Tregs,
further contributing to the disequilibrium between the pro-
and anti-inflammatory processes [36].
A clear shift exists in the cytokine homeostasis in a broad
spectrum of autoimmune conditions, fueling the predomi-
nance of proinflammatory cells versus Tregs [37–46].
5. Cytokine Imbalance,
Regulatory/Effector Cells in
Various Well-Defined Systemic
Autoimmune Diseases
5.1. Sjo¨gren’s Syndrome (SS). Sjo¨gren’s syndrome (SS) is a
chronic, slowly progressive, systemic autoimmune disease
that predominantly affects middle-aged women [47]. SS is
characterized by mononuclear infiltration and destruction
of the exocrine glands, resulting in dry mouth, keratocon-
junctivitis sicca, and the presence of other exocrinopathic
symptoms [47]. In the pathogenesis, different subsets of
T and B lymphocytes and monocytes play a pivotal role.
Increased cell activation, disproportional programmed cell
death, and faulty autoantigen scavenging are important in the
pathogenesis and processes that are partly driven by a skewed
cytokine milieu [48, 49]. A group of peripheral cytokines,
chemokines, and growth factors have been implicated in
the pathogenesis of SS, contributing to the perpetuation of
the cellular and humoral autoimmune processes [49–56].
Skewed T-cell subsets and cytokine imbalance seem to play
important roles in an orchestrated proinflammatory cascade
in SS. Among circulating cytokines, high IFN-𝛾, along with
reduced levels of IL-10, has been described in SS [53].
Moreover, circulating cytokines have the ability to distinguish
SS patients with ectopic salivary gland germinal centers, a
possible forerunner of lymphoma development in the disease
[35, 46, 55]. In patients with SS the following mediators seem
to be increased compared to healthy subjects: IL-1𝛽, IL-2, IL-
6, IL-15, IFN-𝛾, and CCL4 (MIP-1𝛽) [35]. pSS patients with
ectopic germinal center formation were distinguished from
healthy individuals by higher levels of IL-4, IL-10, GM-CSF,
IFN-𝛼, CCL3 (MIP-1𝛼), CCL11 (eotaxin), and B-cell activat-
ing factor (BAFF/BLyS), while germinal center positive and
negative pSS patients differed in CCL2 (MCP-1) expression.
The biomarkers having the strongest discriminatory power
amongst SS patients with or without ectopic salivary gland
germinal centers were CCL11 (eotaxin) and IFN-𝛾, as well as
BAFF/BLyS [35]. Taken together, these findings suggest that a
group of mediators (e.g., cytokines and chemokines) has the
ability to steer a proinflammatory milieu in these patients,
presumably contributing to a derailedTh17/Treg balance.
5.2. Systemic Sclerosis. Systemic sclerosis (SSc) is a systemic
disease of autoimmune pathogenesis, characterized by exces-
sive extracellular matrix deposition and damage of the small
blood vessels, leading to inflammatory processes, dominantly
in the skin and visceral organs, such as the heart, lungs, or
kidneys [57, 58]. Immunoregulatory abnormalities have been
depicted in the pathogenesis of SSc [59–62]. Disorders of
the immune system lead to chronic inflammatory processes,
abnormal T-cell activation, B-cell abnormalities, abundant
production of proinflammatory cytokines (e.g., IL-4), and
the production of characteristic autoantibodies. Tregs with
impaired function have been shown to play a role in the
initiation and perpetuation of the disease [61, 62], while
increased levels of circulating Th17 cell have been described,
along with elevated IL-17 serum concentrations [63, 64]. An
altered balance of the Th1 and Th2 cytokines may also be
responsible for the development of fibrosis [65]. Patients
with SSc had higher percentages of activated T cells, in
addition to a population shift between the effector and reg-
ulatory T cells. IncreasedTh17 cell percentages, together with
decreased levels of Th1, as well as regulatory T-cell subsets
were characteristic of these patients [66]. Interestingly, the
functional assessment of Tregs identified that the suppressor
activity of Tregs was clearly decreased in SSc, compared
to that of healthy individuals. Our data suggest that the
increasedTh17/Treg ratio and the altered regulatory function
of Treg cells play an important role in the development and
progression of SSc [40, 66, 67].
5.3. Mixed Connective Tissue Disease. In mixed connective
tissue disease (MCTD) the most frequently observed symp-
toms are arthritis, Raynaud’s phenomenon, myositis, esopha-
geal dysmotility, and acrosclerosis along with the presence of
autoantibodies reactive with U1 small nuclear RNP (U1RNP)
autoantigens [68–76]. Previously we assessed serum cyto-
kines and intracellular cytokine production of CD4+ and
CD8+ T cells in patients with MCTD [76]. Serum concen-
trations of both type 1 and type 2 cytokines were significantly
higher in patients with MCTD than in healthy controls. The
percentage of IL-10-producing CD4+ and CD8+ T cells was
higher in patients than in controls. In addition, CD4+ and
CD8+ T cells from patients with active MCTD produced
significantly more IL-10 than cells in patients with inactive
disease or in healthy individuals [76]. MCTD is characterized
by a wide spectrum of T-cell abnormalities, which becomes
explicit in the active phase of the disease. Concerning the
role of immunoregulatory abnormalities in the pathogenesis,
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we assessed Tregs in patients with MCTD. The percentage
and the absolute number of natural Treg cells were lower
in patients than in healthy controls which further decreased
in patients with active disease. Interestingly, we saw an
increase in inducible, IL-10 secreting CD4+IL-10+ Tr1 cells
in patients with MCTD. The Tr1 cells ratio further increased
in patients with active disease. As we indicated in patients
with UCTD, we believe that elevated Tr1 cell percentages
could be a compensatory mechanism aiming to restore the
balance between type 1 and type 2 cytokines inMCTD [18]. In
subsets of MCTD patients, serum levels of IFN-𝛾 and TNF-
𝛼 were increased along with reduced number of Tregs. The
decreased levels of regulatory T cells, alongwith the increased
expression of proinflammatory cytokines, may play a role in
the pathogenesis of immune mediated inner ear disorders in
MCTD [77].
Serum and intracellular cytokine assessment, reflecting
immune-regulatory abnormalities, are valuable biomarkers
to assess disease activity in MCTD and are also capable of
subcategorizing these patients [78].
5.4. Systemic Lupus Erythematosus (SLE). SLE is a hetero-
geneous, systemic autoimmune disease with various organ
involvements, encompassing mild to moderate forms and
also severe, progressive variants [79–81]. A great variety of
cytokines have also been implicated in the pathogenesis of
SLE, amongst others, BAFF/BLyS, TNF-𝛼, IFN-𝛼, IFN-𝛾, IL-
12, IL-23, IL-18, IL-6, IL-10, and IL-17 [82, 83].
Pinpointing the key role of the interferon signature in
SLE, interferon regulatory factor-5 (IRF5) has been linked
to the increased production of interferon- (IFN-) 𝛼, and
STAT4 to the increased sensitivity to IFN-𝛼 [84–86]. Patients
with disease flare had significant alterations in a wide variety
of soluble mediators at baseline with significantly higher
levels of proinflammatory mediators, including Th1-, Th2-
, and Th17-type cytokines, already several weeks before the
appearance of clinical flare compared to clinically stable
patients [87]. Regulatory cytokines, including IL-10 and
TGF-𝛽, were higher in nonflare SLE patients [87]. Treg-cell
number and function have been shown to be impaired in
SLE [88–90] along with increases in Th17 cells and serum
IL-17 concentrations, in particular in patients with disease
flare [91–93]. The Th17 and Treg ratio indicates that SLE is
associated with a reduction in the levels and function of
immunosuppressive Treg cells together with an increase in
the proinflammatoryTh17 cells [94].
As we have illustrated, in all these various patient groups
with autoimmune conditions, we could identify a circu-
lating cytokine imbalance, a proinflammatory milieu, and
the development of Th17 cells along with the reduction
in numbers/function of Tregs. The simultaneous, opposing
effect of Th17 cells and Tregs has a strong impact on immune
homeostasis, deciding and controlling the development of
autoimmunity in these patients.
6. Dendritic Cells and Autoimmunity
Dendritic cells (DC) are generally divided into two main
classes, the plasmacytoid DCs (pDCs) that react to viral
infections by secreting large amounts of type I interferons
and conventional or classical DCs (cDCs) that are important
for initiating immune responses through their ability to
take up and present antigen to antigen-specific T cells. For
efficient priming of T cells and induction of effector cells,
the cDCs have to become activated via signals delivered
through pathogen recognition receptors such as toll-like
receptors (TLRs). Activated cDCs express large amounts of
peptide-MHC complexes on their surface and in addition
upregulate costimulator molecules such as CD80 and CD86
for efficient priming of antigen specific T cells. Bacterial and
viral infections produce a large amount of TLR ligands, such
as LPS (TLR2), CpG (TLR9), or dsRNA (TLR3), resulting
in activation of cDCs and efficient induction of effector T
cells. In the absence of activation, however, it is believed that
cDCs instead promote tolerance, through either induction of
Treg or T-cell unresponsiveness [95–97]. cDCs therefore play
a central role in determining the outcome of the immune
response and whether the resulting T-cell responses are
immunogenic or tolerogenic.
6.1. Subsets of DCs. Since their initial discovery by Steinman
in the early 70s [98], a growing body of information now
results in cDCs being divided into subsets based on tissue
distribution, surface receptor expression, and functional
profiling. In general, cDCs can be divided into lymphoid
tissue DC (LT-DCs), in addition to nonlymphoid tissue
DC (NLT-DC), or migratory DCs, which source antigen in
the periphery and subsequently migrate to draining LN for
T-cell priming. LT-DCs were initially divided into subsets
based on expression of CD8𝛼 [99] and CD4 [100]. These
makers are, however, not optimal when classifying NLT
DCs in peripheral organ, with expression of the integrins
CD103 and CD11b being more efficient at separating NLT
DC populations [101, 102]. While a number of different
surface marks have been evaluated, it now seems that the
chemokine receptor Xcr1 is one of the more selective makers
for identifying LT CD8𝛼+ DC and the related NLT CD103+
DCpopulation [103, 104] and that the integrin Sirpa (CD172a)
can be used as a marker for CD4+/CD11b+ DC [105]. The
expression of the markers Xcr1 and Sirpa has the added
advantage of being conserved on homologous DC subsets in
other species such as man [106, 107], macaques [108], and
sheep [109], making for a more unified DC nomenclature
across the species.
Both Xcr1+ and Sirpa+ DCs efficiently present antigens to
CD4+ T cells [110].However, functional analysis has indicated
that only the Xcr1+ DC excel at cross-presenting antigen to
CD8+ T cell and have subsequently been referred to as cross-
presenting DCs [110, 111]. Similar observations have also been
made in peripheral tissue with NLT Xcr1+ DC (defined as
CD103+ DC) being better at presenting antigen to CD8+ T
cells [112]. Whether the same functional difference remains
conserved on DC subsets in humans remains a matter of
debate, with some studies demonstrating that Xcr1+ DC are
better at cross-presenting antigens [107], while others have
shown similar cross-presentation abilities inXcr1+ and Sirpa+
DCs [113].
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Dendritic cells have been suggested to be involved in
the onset of several different autoimmune diseases [114].
However, themechanisms bywhichDCplay a role in autoim-
munity may vary between diseases. As antigen presenting
cells, DCmay directly prime autoimmune T cells, but as indi-
cated earlier they may also induce Tregs that inhibit autoim-
mune disease. In addition, DCsmay secrete proinflammatory
cytokines upon activation which may be directly involved
in disease progression. Here we depict a few examples on
the possible involvement of DCs, the progression of type 1
diabetes (T1D), and systemic lupus erythematosus (SLE).
6.2. Type 1 Diabetes (T1D). Type 1 diabetes is thought to
be initiated by the presentation of diabetogenic antigens in
the draining pancreatic lymph node (pLN), with subsequent
induction of autoreactive T cells which destroy the pancreatic
𝛽-islet cells leading to loss of insulin production and diabetes.
Conditional depletion of DCs has been reported to prevent
disease onset in diabetes prone NOD mice, suggesting that
DC may be involved in the initial priming of autoreactive T
cells [115]. Interestingly, a recent study observed that Batf3
deficient NOD mice did not develop diabetes [116]. Mice
deficient in the transcription factor Batf3 lack the Xcr1+ LT
and NLT DC populations [117], suggesting involvement of
this DC subset in the onset of disease. Ferris and colleagues
observed that islets of Langerhans contained a minor popu-
lation of Xcr1+ NLT DC, in addition to a major population
of macrophages. Deletion of the Xcr1+ NLT DC in the
NOD.Batf3−/− mice resulted in absence of presentation of
MHC-I epitopes in the pLN and no incidence of diabetes.
These observations are in accordance with previous studies
suggesting that cross priming is required in the pathogenesis
of diabetes [118] and the functional specialization of Xcr1+
NLTDC in terms of cross presenting antigen to CD8+ T cells.
6.3. Systemic Lupus Erythematosus (SLE). While lupus is
generally thought to be an autoantibody driven disease,
studies have shown that certain MHC haplotypes display a
strong association with disease onset suggesting that T cells
may also play a role in the pathogenesis [119]. In lupus prone
MRL.Faslpr mice, depletion of DCs resulted in less severe
disease development with lower glomerular and interstitial
renal disease scores [120]. Interestingly, the authors observed
that DC depletion did not significantly influence T-cell
activation but that T-cell expansion was severely reduced.
Consequently, the immunogenic role of the DCs seems to
outweigh the tolerogenic function of DC in this model of
autoimmunity. It should be noted that depletion of DCs in
thismodel only ameliorated the disease, suggesting that other
cells subsets may be involved in the initiation events. Maybe
more surprising was the observation that DC depleted mice
displayed reduced numbers of plasmablasts in spleen and
inhibited class switching, suggesting that the DCs may be
involved in this process. Previous studies have indicated that
DCmay play a role in plasmablast differentiation in SLE [121],
which corresponds well with the observations by Teichmann
et al. While DCs in autoimmune disease progression tend
to primarily function as antigen presenting cells (APCs) and
activators of T cells, it is clear that their stimulatory effect on
B cells may also affect disease progression.
Type I interferons play amajor role in disease progression
in SLE, and patients with high levels of type I interferon in
serumhavemore severe disease outcome [122]. As highly effi-
cient producers of type I interferons, pDCs have been sug-
gested to be an important source of type I interferon and
disease onset in SLE [123]. In human patients, pDCs have
been observed to accumulate in the tissue lesions suggesting a
possible involvement in lupus [124].Whilemost observations
implicating pDCs in SLE progression have so far been
indirect, a recent paper by Sisirak and colleagues showed
that impairing pDC function in a murine SLE model nearly
abolished disease manifestations such as glomerulonephritis
and anti-DNA antibodies [125]. These observations clearly
indicate that pDCs are directly involved in SLE pathogenesis
and the induction of autoantibodies.
7. Extracellular Vesicles in
Autoimmune Diseases
Extracellular vesicles (EVs) are heterogeneous, membrane
surrounded structures that can be found in body fluids
and play a crucial role in the intracellular communication
[126, 127]. Based on their morphological parameters and
biogenesis EVs can be categorized as exosomes,microvesicles
(MVs), and apoptotic bodies. Exosomes are the smallest EVs;
their size range is around 50–100 nm, similar to the size of
the viruses. Exosomes are released by exocytosis of multivesi-
cular bodies [128], and they may transfer viruses and
microRNA (miRNA). Exosome markers include lysosomal-
associated membrane protein 1 (LAMP-1), CD63, and CD81.
Among others, several tumor cells and immune cells release
exosomes constitutively or upon activation.
The size range of microvesicles (MVs) is between 100 and
1000 nm, similar to the size of bacteria and immune com-
plexes. Detergent treatment (0.05% Triton X-100) completely
eliminates the MVs; while it does not significantly influence
the immune complexes [129], this method can be used to
discriminate MVs and immune complexes. MVs are gener-
ated by budding of the plasmamembrane. Although platelets,
endothelial cells, and red blood cells are the primary sources
of MVs, many other cells may release these structures as well.
MVs have a central role in the fetomaternal communication
and in the pathogenesis of several autoimmune diseases,
such as RA and SLE. Phosphatidylserine externalization is a
general feature of the MVs. Apoptotic bodies are the largest
EVs; their size range is between 1 and 5𝜇m (the size range
of platelets); they are secreted during apoptosis. Similarly
to MVs apoptotic bodies also express phosphatidylserine
in the outer part of their membrane and they generally
contain DNA. Apoptotic bodies have a central role in the
transfer of DNA and oncogenes between various cells. Flow-
cytometry, western blotting, ELISA, electronmicroscopy, and
mass spectrometry are the most frequently used methods in
the EV research.Despite thewidespread research of EVs there
are still many technical pitfalls and the researchers have to be
especially careful when interpreting their results.
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There are increasing data on the potential pathogenetic
role of MVs in RA and in SLE. Increased number of platelet
derivedMVs (PMVs) in the serum and synovial fluid samples
of patients with RA were reported [130, 131]. The number
of PMVs was increased in the plasma samples of patients
with RA compared to the healthy donors’, and the number
of PMVs correlated with the disease activity [132].The PMVs
have procoagulant activity; therefore PMVs may contribute
to the increased cardiovascular risk in RA. It was recently
published that C-type lectin-like receptor 2 (CLEC-2) is
expressed on the MVs of patients with RA [133], and the
authors suggest using this marker to measure PMVs. In
general, most studies onMVs in RA investigatedmorpholog-
ical features and there are only relatively little data available
about their biological effects. Fibroblast-like synoviocytes of
patients with RA produced B-cell-activating factor upon MP
treatment, suggesting that these structures may contribute to
the activation of the adaptive immune response in RA [134].
The number of MPs is increased in SLE and the protein
composition of them is different from the healthy donors’
[135]. The number of endothelial MVs was measured in a
recently published prospective study by flow cytometry [136].
The number of EMPs was higher in the samples of patients
with SLE than in the samples of healthy donors. Disease
activity decreased during the study and in parallel the num-
ber of EMPs decreased. Importantly, the clinical disease activ-
ity (BILAG-2004 and SLEDAI-2K scores) did not correlate
with the EMP numbers. These data suggest that endothelial
dysfunction may improve with the appropriate reduction of
the inflammation in SLE. Increased number ofMVswere also
reported in systemic sclerosis [137] and polymyositis [138]
and in Sjo¨gren’s syndrome [139].
8. Conclusions
The intricate interplay of various proinflammatory cytokines
and chemokines, orchestrated by key regulators of the
immune system (e.g., dendritic cell subsets), can lead to the
imbalance between regulatory (e.g., Tregs) and proinflam-
matory cells (e.g., Th17 cells). This vicious circle can further
perpetuate autoimmune processes, which, on a susceptible
genetic background, can lead to the development of a full-
blown autoimmune disease. Other novel mediators, denoted
as extracellular vesicles, seem to have a pivotal role in the
pathogenesis, as well. The fine mapping of these mediators
does not just help us to understand the pathogenesis of these
diseases, but we believe that long, empirical therapies can
be replaced by optimized combination therapies through
personalized proinflammatory cytokine, extracellular vesicle
targeting, or dendritic cell manipulation. We believe that this
approach will aid in the diagnosis and therapy design in
autoimmune diseases and will provide an advanced disease
management in the future.
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